Herpes Clinical Trial
Official title:
Phase II Clinical Trial of Versabase/Sarracenia Purpurea Versus Placebo
This study will compare efficacy of versabase gel with 20% sarracenia purpurea versus placebo applied every 3-4 hours to herpes lesions.
Patients screened for hsv one or two. Patients with herpes given a 1/8 oz of gel. Researcher does not know which is active and which is placebo (placebo is actually just versabase gel). Patent applies gel to lesions every 3-4 hours. Returns to clinic on days 3, 5, and 14 for evaluation. Up to 50 patients may be enrolled. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04664127 -
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
|
||
| Completed |
NCT01321502 -
Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions
|
N/A | |
| Completed |
NCT01321515 -
Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions
|
N/A | |
| Completed |
NCT02092233 -
A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients
|
N/A | |
| Completed |
NCT00362596 -
A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand
|
Phase 4 |